Home/Filings/4/0001214659-21-003944
4//SEC Filing

Wasoff Evan L 4

Accession 0001214659-21-003944

CIK 0001625288other

Filed

Apr 4, 8:00 PM ET

Accepted

Apr 5, 5:34 PM ET

Size

8.4 KB

Accession

0001214659-21-003944

Insider Transaction Report

Form 4
Period: 2021-04-01
Wasoff Evan L
Chief Financial Officer
Transactions
  • Award

    Common Stock

    2021-04-01+1,000,0002,000,000 total
Holdings
  • Options to purchase common stock (right to buy)

    Exercise: $0.08From: 2020-08-19Exp: 2027-08-19Common Stock (1,500,000 underlying)
    1,500,000
  • Stock option - right to buy

    Exercise: $0.54From: 2018-07-25Exp: 2025-07-25Common Stock (420,000 underlying)
    420,000
  • Stock option - right to buy

    Exercise: $0.66From: 2018-10-26Exp: 2025-10-26Common Stock (200,000 underlying)
    200,000
Footnotes (1)
  • [F1]1. Issued in lieu of compensation for services.

Documents

1 file

Issuer

NEXIEN BIOPHARMA, INC.

CIK 0001625288

Entity typeother

Related Parties

1
  • filerCIK 0001719738

Filing Metadata

Form type
4
Filed
Apr 4, 8:00 PM ET
Accepted
Apr 5, 5:34 PM ET
Size
8.4 KB